Univariate and multivariate analyses of factors associated with mortality in 108 patients with EBV+ T/NK-LD
| . | Univariate analysis . | Multivariate analysis† . | ||
|---|---|---|---|---|
| OR (95% CI) . | P* . | OR (95% CI) . | P‡ . | |
| Female sex | 1.40 (0.98-1.97) | .048 | 1.26 (0.48-3.31) | .64 |
| Age at disease onset (≥ 8 years)§ | 1.63 (1.17-2.28) | .003 | 4.43 (1.61-12.2) | .004 |
| Past history of infectious mononucleosis | 0.62 (0.35-1.11) | .093 | 0.36 (0.12-1.02) | .054 |
| Primary infection at diagnosis | 0.47 (0.18-1.20) | .079 | 0.32 (0.08-1.25) | .10 |
| Clinical entity at diagnosis | ||||
| CAEBV | 1.12 (0.90-1.39) | NS | ||
| HLH | 0.65 (0.24-1.77) | NS | ||
| Severe mosquito bite allergy | 1.04 (0.30-3.65) | NS | ||
| Hydroa vacciniforme | 0.43 (0.05-4.03) | NS | ||
| T-cell infection | 1.13 (0.69-1.71) | NS | ||
| NK-cell infection | 0.95 (0.69-1.30) | NS | ||
| EBV DNA in mononuclear cells (≥ 104.5 copies/μg DNA) | 1.16 (0.79-1.71) | NS | ||
| EBV DNA in plasma (≥ 103.5 copies/mL) | 1.23 (0.84-1.72) | NS | ||
| EBV monoclonality | 1.08 (0.89-1.31) | NS | ||
| TCR rearrangement | 1.13 (0.73-1.76) | NS | ||
| Chromosomal aberration | 1.92 (0.34-10.9) | NS | ||
| Symptoms and signs at diagnosis | ||||
| Fever | 1.10 (0.98-1.24) | NS | ||
| Liver dysfunction | 1.33 (1.09-1.63) | .006 | 4.25 (1.23-14.7) | .022 |
| Splenomegaly | 1.38 (1.01-1.88) | .033 | ¶ | |
| Anemia | 1.84 (1.18-2.88) | .005 | 1.36 (0.31-6.01) | .68 |
| Thrombocytopenia | 1.75 (1.13-2.71) | .009 | 1.80 (0.44-7.33) | .41 |
| Lymphadenopathy | 1.24 (0.77-2.00) | NS | ||
| Hemophagocytic syndrome | 1.30 (0.72-2.32) | NS | ||
| Hypersensitivity to mosquito bites | 0.89 (0.69-1.15) | NS | ||
| Hydroa vacciniforme-like eruption | 0.86 (0.34-1.97) | NS | ||
| Chemotherapy | 0.84 (0.53-1.34) | NS | ||
| HSCT | 0.67 (0.045-0.98) | .022 | 0.34 (0.12-0.96) | .041 |
| T-cell infection group | 0.54 (0.30-0.97) | .021 | ||
| NK-cell infection group | 0.83 (0.51-1.34) | NS | ||
| . | Univariate analysis . | Multivariate analysis† . | ||
|---|---|---|---|---|
| OR (95% CI) . | P* . | OR (95% CI) . | P‡ . | |
| Female sex | 1.40 (0.98-1.97) | .048 | 1.26 (0.48-3.31) | .64 |
| Age at disease onset (≥ 8 years)§ | 1.63 (1.17-2.28) | .003 | 4.43 (1.61-12.2) | .004 |
| Past history of infectious mononucleosis | 0.62 (0.35-1.11) | .093 | 0.36 (0.12-1.02) | .054 |
| Primary infection at diagnosis | 0.47 (0.18-1.20) | .079 | 0.32 (0.08-1.25) | .10 |
| Clinical entity at diagnosis | ||||
| CAEBV | 1.12 (0.90-1.39) | NS | ||
| HLH | 0.65 (0.24-1.77) | NS | ||
| Severe mosquito bite allergy | 1.04 (0.30-3.65) | NS | ||
| Hydroa vacciniforme | 0.43 (0.05-4.03) | NS | ||
| T-cell infection | 1.13 (0.69-1.71) | NS | ||
| NK-cell infection | 0.95 (0.69-1.30) | NS | ||
| EBV DNA in mononuclear cells (≥ 104.5 copies/μg DNA) | 1.16 (0.79-1.71) | NS | ||
| EBV DNA in plasma (≥ 103.5 copies/mL) | 1.23 (0.84-1.72) | NS | ||
| EBV monoclonality | 1.08 (0.89-1.31) | NS | ||
| TCR rearrangement | 1.13 (0.73-1.76) | NS | ||
| Chromosomal aberration | 1.92 (0.34-10.9) | NS | ||
| Symptoms and signs at diagnosis | ||||
| Fever | 1.10 (0.98-1.24) | NS | ||
| Liver dysfunction | 1.33 (1.09-1.63) | .006 | 4.25 (1.23-14.7) | .022 |
| Splenomegaly | 1.38 (1.01-1.88) | .033 | ¶ | |
| Anemia | 1.84 (1.18-2.88) | .005 | 1.36 (0.31-6.01) | .68 |
| Thrombocytopenia | 1.75 (1.13-2.71) | .009 | 1.80 (0.44-7.33) | .41 |
| Lymphadenopathy | 1.24 (0.77-2.00) | NS | ||
| Hemophagocytic syndrome | 1.30 (0.72-2.32) | NS | ||
| Hypersensitivity to mosquito bites | 0.89 (0.69-1.15) | NS | ||
| Hydroa vacciniforme-like eruption | 0.86 (0.34-1.97) | NS | ||
| Chemotherapy | 0.84 (0.53-1.34) | NS | ||
| HSCT | 0.67 (0.045-0.98) | .022 | 0.34 (0.12-0.96) | .041 |
| T-cell infection group | 0.54 (0.30-0.97) | .021 | ||
| NK-cell infection group | 0.83 (0.51-1.34) | NS | ||
NS indicates not significant.
P < .10 are shown; P < .05 (shown in bold) are statistically significant.
For multivariate analysis, factors with P < .10 were included.
P < .05 (shown in bold) are statistically significant.
Stratified onset ages were analyzed in advance, and ≥ 8 years was chosen as the age factor.
Splenomegaly was excluded from multivariate analysis, because this factor was closely associated with anemia, thrombocytopenia, and liver dysfunction.